Outcome in acute myeloid leukemia (AML) with t(8;21) by number of high-dose ara-C consolidations.*
| . | Number of High-Dose Ara-C Courses . | ||
|---|---|---|---|
| Parameter . | 1 . | ≥ 3 . | Pvalue . |
| *Data from Byrd et al.26 | |||
| Abbreviations: CR, complete remission; DFS, disease-free survival. | |||
| Relapse, % | 62 | 19 | 0.004 |
| Median CR duration (mos) | 10.5 | > 35 | |
| 5-year DFS, % | 38 | 61 | 0.03 |
| Median survival (mos) | 24 | > 43 | |
| 5-year survival, % | 44 | 76 | 0.04 |
| . | Number of High-Dose Ara-C Courses . | ||
|---|---|---|---|
| Parameter . | 1 . | ≥ 3 . | Pvalue . |
| *Data from Byrd et al.26 | |||
| Abbreviations: CR, complete remission; DFS, disease-free survival. | |||
| Relapse, % | 62 | 19 | 0.004 |
| Median CR duration (mos) | 10.5 | > 35 | |
| 5-year DFS, % | 38 | 61 | 0.03 |
| Median survival (mos) | 24 | > 43 | |
| 5-year survival, % | 44 | 76 | 0.04 |